Apixaban versus warfarin in patients with atrial fibrillation.

B Granger, Christopher; Alexander, J.; J.V. McMurray, John; Lopes, R.; Hylek, E.; Hanna, M.; Al-Khalidi, H.; Ansell, J.; Atar, D.; Avezum, Á.; Bahit, M.; Diaz, Rafael; Easton, J.; Ezekowitz, J.; C. Flaker, Greg; A. Garcia, David; Geraldes, M.; Gersh, B.; Golitsyn, S.; Goto, S.; Hermosillo, A.; Hohnloser, S.; D. Horowitz, John; Mohan, Puneet; Janský, P.; S. Lewis, Basil; López-Sendón, J.; Pais, P.; Parkhomenko, A.; Verheugt, F.; Zhu, Jun; Wallentin, L.

doi:10.1056/NEJMoa1107039

Public

Apixaban versus warfarin in patients with atrial fibrillation.

Shared by NobleBlocks on Sep 14, 2011 • 12:00 AM UTC

Authors:

Christopher B Granger

J. Alexander

John J.V. McMurray

Abstract

BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. METHO...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!